Icon Bioscience Appoints Clinical Development VP

Icon Bioscience, Inc. (IBI) has appointed Wendy Yee Murahashi, M.D. as vice president of Clinical Development. Dr. Murahashi will lead the company’s clinical development programs based on IBI’s Verisome drug delivery technology.
 
“As we near the completion of our pivotal Phase II/III trial evaluating IBI-10090 for the treatment of inflammation in patients undergoing cataract surgery, Wendy brings to IBI relevant clinical experience that will provide immediate value to IBI,” said William S. White, chief executive officer of Icon Bioscience. “She will also be a tremendous asset to IBI as we prepare in 2012 to initiate our clinical programs into new areas, including uveitis and glaucoma.”
 
Dr. Murahashi joins the company from Genentech/Roche, where she served as a medical director responsible for clinical activities for Lucentis. Previously she served as a clinical instructor at the Portland VA Hospital/Casey Eye Institute.